AVIR

Atea Pharmaceuticals, Inc.

• TipRanks·3d ago

  Top Atea Pharmaceuticals Insider Quietly Boosts Stake in Bold New Move

• PUBT·3d ago

  Atea director Polly Murphy buys 6,100 shares worth $25,446.15

• TipRanks·5d ago

  Atea Pharmaceuticals (AVIR) Receives a Hold from Morgan Stanley

• Simply Wall St·05/14 10:37

  We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully

• TipRanks·05/14 00:31

  Atea Pharmaceuticals Sets Up Catalyst-Rich 2026 Earnings Call

• TipRanks·05/13 13:30

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR)

• PUBT·05/13 11:04

  Atea presents new HCV trial data on bemnifosbuvir-ruzasvir at EASL 2026

• Seeking Alpha·05/13 04:31

  Atea anticipates Phase III C-BEYOND midyear and C-FORWARD year-end readouts while projecting cash runway through 2027

• Benzinga·05/12 21:17

  Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript

• Reuters·05/12 21:04

  BRIEF-Atea Pharmaceuticals Reports First Quarter 2026 Financial Results

• Reuters·05/12 20:27

  Atea Pharmaceuticals Q1 net loss widens on higher R&D spending

• Seeking Alpha·05/12 20:21

  Atea Pharmaceuticals GAAP EPS of -$0.57 beats by $0.02

• Reuters·05/12 20:17

  ATEA PHARMACEUTICALS Q1 OPERATING EXPENSES USD 48.008 MILLION

• Reuters·05/12 20:17

  ATEA PHARMACEUTICALS Q1 EPS USD -0.57

• Dow Jones·05/12 20:05

  Press Release: Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update